Testing metformin with two newer diabetes drugs
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial is testing if adding a combination of SGLT-2 inhibitor and GLP-1 receptor agonist to metformin can improve blood sugar control in people with type 2 diabetes who are not meeting their goals on metformin alone or with one other pill.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes and are between 18 and 75 years old.
- Your body mass index (BMI) is 20 or higher.
- You have been taking at least 1000 mg of metformin daily for 8 weeks or more, with or without one other diabetes pill (but not an SGLT-2i or oral GLP-1RA).
- Your average blood sugar over 2–3 months (HbA1c) is between 7.5% and 11.0%.
- You have not used insulin in the past week, or GLP-1RA or SGLT-2i drugs in the past 12 weeks.
- You do not have serious kidney, liver, or pancreas problems, and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination pill that includes three medications to lower blood sugar in people with type 2 diabetes. It aims to see if this combination is safe and effective for Chinese patients.
This study looks at the safety and effectiveness of adding a third oral diabetes medicine to your current two-drug combination. It is for adults with type 2 diabetes whose blood sugar is not well controlled on metformin plus one other pill.
This trial compares adding a new pill (cofrogliptin) to increasing your current metformin dose, for people whose blood sugar is still too high despite taking an SGLT2 inhibitor and a low dose of metformin. The goal is to see which option works better and is safer.
This trial tests a combination of three diabetes medicines (henagliflozin proline, retagliptin, and metformin) for people newly diagnosed with type 2 diabetes. The goal is to see how well the combination controls blood sugar and to check its safety.
This study tests a combination of three diabetes medicines (empagliflozin, linagliptin, and metformin) to see if it helps control blood sugar in people with type 2 diabetes. It may be an option if your current treatment isn't working well enough.
This trial tests a combination of three common diabetes medications (metformin, an SGLT2 inhibitor, and a TZD) to see how well they work together and if they are safe. It may help people with type 2 diabetes who need better blood sugar control.
Hear when a new T2DM (Type 2 Diabetes Mellitus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.